| Literature DB >> 35215291 |
Walaa A Negm1, Aya H El-Kadem2, Engy Elekhnawy3, Nashwah G M Attallah4, Gadah Abdulaziz Al-Hamoud5, Thanaa A El-Masry2, Ahmed Zayed1,6.
Abstract
A wound is a complicated bioprocess resulting in significant tissue damage, which is worsened by a secondary bacterial infection, commonly Pseudomonas aeruginosa and Staphylococcus aureus. The goal of our study was to investigate the metabolic profile and possible wound-healing effect of Sanguisorba officinalis roots rhoifolin rich fraction (RRF). The LC-ESI-MS/MS analysis of S. officinalis roots crude ethanol extract resulted in a tentative identification of 56 bioactive metabolites, while a major flavonoid fraction was isolated by column chromatography and identified by thin-layer chromatography coupled with electrospray ionization/mass spectrometry (TLC-ESI/MS), where rhoifolin was the major component representing 94.5% of its content. The antibiofilm activity of RRF on the mono-species and dual-species biofilm of P. aeruginosa and S. aureus was investigated. RRF exhibited inhibitory activity on P. aeruginosa and S. aureus mono-species biofilm at 2× minimum inhibitory concentration (MIC) and 4× MIC values. It also significantly inhibited the dual-species biofilm at 4× MIC values. Moreover, the wound-healing characteristics of RRF gel formulation were investigated. Rats were randomly allocated into four groups (eight rats in each): Untreated control; Blank gel; Betadine cream, and RRF gel groups. Animals were anesthetized, and full-thickness excisional skin wounds were created on the shaved area in the dorsal skin. The gels were topically applied to the wound's surface daily for 10 days. The results demonstrated that RRF had a promising wound-healing effect by up-regulating the platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), keratinocyte growth factor (KGF), and fibronectin, while metalloproteinase-1 (MMP-1), interleukin-6 (IL-6), IL-1β, and nitric oxide (NO) levels were suppressed. It also enhanced the immune staining of transforming growth factor (TGF-β) and improved histopathological findings. Furthermore, it displayed an immunomodulatory action on lipopolysaccharide-induced peripheral blood mononuclear cells. Hence, the wound-healing effect of rhoifolin was confirmed by supporting re-epithelization, angiogenesis, antibacterial, immunomodulatory, and anti-inflammatory activities.Entities:
Keywords: LC-MS/MS; MMP-1; TGF-β; anti-inflammatory; antibiofilm; immunomodulatory
Year: 2022 PMID: 35215291 PMCID: PMC8874642 DOI: 10.3390/ph15020178
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
List of tentatively identified metabolites in ethanol extract of Sanguisorba officinalis roots analyzed by LC-ESI-MS/MS.
| No. | Peak Area (%) | Identified | RT (min) | Molecular Formula | [M − H]− | [M + H]+ | MS2 | Ref | |
|---|---|---|---|---|---|---|---|---|---|
| Phenolic acids/glycoside | |||||||||
| 1 | 0.11 | Syringoylmalic acid | 2.7 | C13H14O9 | 315.070 | 125.0, 153.0, 169.1, 297.1 | [ | ||
| 2 | 0.07 | Rosmarinic acid | 4.1 | C18H16O8 | 359.096 | 150.9, 169.0, 188.9, 314.9 | --- * | ||
| 3 | 0.01 | Homogenentisic acid | 4.46 | C8H8O4 | 167.034 | 82.9, 109.0, 122.9, 122.9, 149.0 | --- | ||
| 4 | 0.2 | Syringic acid | 7.21 | C9H10O5 | 199.059 | 59.0, 65.0, 95.0, 107.0, 123.0, 125.0, 135.0, 139.0, 140.0, 152.0, 167.0 | [ | ||
| 5 | 0.22 | 1-O- | 14.32 | C17H22O10 | 387.178 | 77.0, 93.0, 105.0, 119.0, 121.0, 147.0 | --- | ||
| 6 | 0.21 | Unknown phenolic acids/glycoside | 21.61 | C16H24O7 | 329.159 | 111.0, 129.0, 139.0, 157.0, 185.0 | --- | ||
| Alkaloids and related metabolites | |||||||||
| 7 | 0.07 | Harmaline | 1.21 | C13H14N2O | 215.099 | 127.1, 144.0, 157.0, 183.0 | --- | ||
| 8 | 0.03 | 3-Methyl xanthine | 7.21 | C6H6N4O2 | 167.034 | 60.0, 149.0, 152.0 | --- | ||
| Flavonoids and related metabolites | |||||||||
| 9 | 0.02 | Quercetin-3-D-xyloside | 1.34 | C20H18O11 | 433.038 | 299.9, 300.9, 366.9 | --- | ||
| 10 | 0.12 | Epigallocatechin | 2.71 | C15H14O7 | 305.063 | 125.0, 165.0, 179.0, 221.0, 261.0 | --- | ||
| 11 | 0.07 | Eriodictyol-7- | 3.71 | C21H22O11 | 449.110 | 229.0, 259.0, 269.0, 274.9, 287.0 | --- | ||
| 12 | 0.81 | Procyanidin B2 | 4.29 | C30H26O12 | 577.131 | 125.0, 137.0, 161.0, 205.0, 245.0, 247.0, 273.0, 275.0, 287.0, 289.0, 299.0, 339.0, 381.1, 407.0, 425.0, 451.1, 559.1 | --- | ||
| 13 | 0.02 | Procyanidin C1 | 4.47 | C45H38O18 | 865.208 | 287.0, 413.1, 425.1, 575.1, 575.1 577.1, 695.1, 713.1, 713.1, 739.1 | --- | ||
| 14 | 3.3 | (-)-Epicatechin | 4.62 | C15H14O6 | 289.071 | 57.0, 81.0, 83.0, 95.1, 97.0, 108.0, 123.0, 125.0, 135.0, 137.0, 139.0, 149.0, 151.0, 161.0, 162.0, 164.0, 165.0, 167.0, 175.0, 179.0, 187.0, 188.0, 202.0, 203.0, 205.0, 220.9, 221.0, 227.0, 230.0, 247.0 | --- | ||
| 15 | 0.51 | Catechin | 4.73 | C15H14O6 | 291.085 | 68.0 77.0, 91.0, 93.0, 105.0, 111.0, 115.0, 119.0, 123.0, 127.0, 133.0, 137.0, 137.0, 139.0, 143.0, 147.0 151.0, 161.0, 163.0, 165.0, 177.0 179.0, 189.0, 207.0, 249.0, 273.0 | --- | ||
| 16 | 0.2 | 3,5,7-trihydroxy-4′-methoxyflavone | 5.12 | C16H12O6 | 298.982 | 79.9, 181.0, 283.9 | --- | ||
| 17 | 0.003 | Luteolin-6- | 5.2 | C21H20O11 | 447.094 | 174.9, 299.9, 303.0, 315.0, 327.0, 378.9, 401.1 | --- | ||
| 18 | 0.12 | Procyanidin B1 | 5.46 | C30H26O12 | 577.134 | 125.0, 165.0, 287.0, 289.0, 299.0, 381.1, 407.1, 425.1, 451.1 | --- | ||
| 19 | 0.02 | Naringenin-7- | 5.8 | C21H22O10 | 433.114 | 123.0, 135.0, 163.0, 188.9, 237.0, 253.0, 271.0, 296.9 | --- | ||
| 20 | 0.2 | Isookanin-7-glucoside | 5.85 | C21H22O11 | 449.109 | 150.9, 178.9, 259.0, 269.0, 287.0 | --- | ||
| 21 | 0.06 | Kaempferol-3- | 6.53 | C21H18O12 | 461.072 | 188.9, 256.9, 313.9, 324.9, 328.0, 329.0, 392.8 | --- | ||
| 22 | 0.01 | Quercetin-3- | 7.17 | C20H18O11 | 435.164 | 273.0, 302.9, 303.0 | --- | ||
| 23 | 0.03 | Phlorizin | 7.77 | C21H24O10 | 435.129 | 167.0, 180.0, 271.0, 273.0 | --- | ||
| 24 | 0.03 | Isorhamnetin-3- | 6.78 | C22H22O12 | 477.142 | 163.0, 169.0, 313.0, 324.9, 364.8, 432.8 | --- | ||
| 25 | 0.01 | 4,5′-dihydroxy-3-methoxy-3′-glucopyranosylstilbene | 6.85 | C21H24O9 | 419.099 | 259.0, 282.9, 287.0, 351.0 | --- | ||
| 26 | 0.003 | Rhoifolin (Apigenin 7- | 7.24 | C27H30O14 | 577.213 | 112.9, 356.9 | --- | ||
| 27 | 0.004 | Neohesperidin dihydrochalcone | 8.08 | C28H36O15 | 611.141 | 400.8, 520.8, 565.0 | --- | ||
| 28 | 0.03 | Kaempferol-3- | 8.13 | C20H18O10 | 417.117 | 119.0, 218.9, 255.0, 280.9, 286.9, 354.9 | --- | ||
| 29 | 0.01 | 4-deoxyphloridzin | 8.29 | C21H24O9 | 419.133 | 151.0, 257.0, 351.0 | --- | ||
| 30 | 0.02 | Naringenin | 9.94 | C15H12O5 | 271.062 | 93.0, 119.0, 151.0, 225.1, 253.0 | --- | ||
| 31 | 0.19 | 4,4′-Di- | 10.22 | C16H10O8 | 331.042 | 225.0, 245.0, 270.0011:54 271.0, 299.0, 300.9, 316.0 | --- | ||
| 32 | 0.08 | 3,3′,4′,5-tetrahydroxy-7-methoxyflavone | 10.23 | C16H12O7 | 316.971 | 317.0 | --- | ||
| 33 | 0.01 | Apigenin | 10.39 | C15H10O5 | 269.043 | 117.0, 269.0, 269.2, 269.2 | --- | ||
| 34 | 0.003 | Cyanidin-3-O-(2″-O- | 12.43 | C26H29O15 | 581.079 | 564.1 | --- | ||
| 35 | 0.01 | Luteolin | 15.93 | C15H10O6 | 287.200 | 137.0, 203.1, 272.1 | --- | ||
| 36 | 0.02 | 3′-Methoxy-4′,5,7-trihydroxyflavonol | 16.87 | C16H12O7 | 317.056 | 299.2, 302.0 | --- | ||
| 37 | 0.01 | E-3,4,5′-Trihydroxy-3′-glucopyranosylstilbene | 19.85 | C20H22O9 | 405.171 | 390.1 | --- | ||
| 38 | 0.04 | 3,5,7-trihydroxy-4′-methoxyflavone | 20.11 | C16H12O6 | 301.141 | 161.0, 285.0 | --- | ||
| Triterpenoids | |||||||||
| 39 | 0.1 | 3-Oxo-15α, 19α-dihydroxyurs-12-en-28-oic acid or 3-oxo-7 | 11.29 | C30H46O5 | 485.328 | 354.9, 372.9, 405.3, 423.3, 455.3 | [ | ||
| 40 | 0.02 | Ziyuglycoside I | 11.35 | C41H66O13 | 765.481 | 585.3, 601.4, 603.3, 604.3 | [ | ||
| 41 | 0.1 | Unknown triterpenoid | 11.96 | C31H50O8 | 549.339 | 421.3, 501.7, 503.3 | |||
| 42 | 0.11 | Lup-12-en-15 | 13.41 | C30H44O6 | 501.319 | 231.1, 341.2, 437.3, 455.3, 465.3, 483.3 | [ | ||
| 43 | 0.3 | Euscaphic acid or Arjunic acid | 13.96 | C30H48O5 | 488.347 | 424.3, 487.3, 488.3 | [ | ||
| 44 | 0.25 | 3-Oxo-23-hydroxyurs-12-en-28-oic acid | 14.22 | C30H46O4 | 471.348 | 213.1, 285.2, 407.3, 425.3, 453.3 | [ | ||
| 45 | 0.07 | Unknown | 15.81 | C30H42O5 | 483.310 | 185.1, 213.1, 233.1, 419.2, 465.2 | |||
| 46 | 0.05 | Sanguisorbigenin | 18.88 | C30H46O3 | 455.351 | 187.1, 189.1, 191.1, 201.1, 409.3, 437.3 | [ | ||
| 47 | 0.11 | 18,19- | 18.98 | C30H44O5 | 485.326 | 187.1, 205.1, 235.1, 367.2, 421.3, 439.3, 467.3 | [ | ||
| 48 | 0.54 | Unknown | 19.74 | C30H44O4 | 469.330 | 147.1, 283.2, 351.2, 405.3, 423.3 | |||
| 49 | 0.23 | Fupenzic acid | 20.35 | C30H44O3 | 453.337 | 119.1, 133.1, 145.1, 173.1, 175.1, 177.1, 205.1, 259.1, 389.3 | [ | ||
| 50 | 0.02 | Ursolic acid | 22.3 | C30H48O3 | 455.355 | 180.9, 248.9, 250.9, 318.9, 409.2 | [ | ||
| Fatty acids | |||||||||
| 51 | 0.32 | Linoleic acid | 21.92 | C18H32O2 | 279.234 | 210.9 | --- | ||
| 52 | 0.7 | Glyceryl palmitate | 23.29 | C19H38O4 | 331.286 | 57.0, 71.0, 85.0, 95.0, 109.0, 123.1, 239.2, 313.2 | --- | ||
| 53 | 0.07 | Glyceryl 2-linolenate | 23.31 | C21H36O4 | 353.263 | --- | |||
| 54 | 0.06 | Oleic acid | 24.19 | C18H34O2 | 281.251 | 213.2, 280.3 | --- | ||
| Others | |||||||||
| 55 | 0.01 | D-Carnitine | 1.2 | C7H15NO3 | 162.112 | 55.0, 59.0, 73.9, 103.0, 127.0 | --- | ||
| 56 | 0.33 | 7-(α-D-Glucopyranosyloxy)-2,3,4,5,6-pentahydroxyheptanoic acid | 1.24 | C13H24O13 | 387.114 | 89.0, 161.0, 179.0, 251.0, 258.9, 263.0, 323.1, 341.1 | --- | ||
| 57 | 0.002 | Unknown | 6.16 | C12H23NO10S3 | 436.088 | 304.0, 388.0 | --- | ||
| 58 | 1.1 | Zingiberoside A | 9.51 | C22H38O12 | 7.6 | 493.225 | 89.0, 131.0, 149.0, 179.0, 191.0, 221.0, 251.0, 288.9, 311.0, 315.1, 356.9, 430.8, 447.2 | --- | |
| 59 | 0.2 | Decanoylsucrose | 10.35 | C22H40O12 | 495.243 | 99.0, 119.0, 131.0, 317.1, 449.2 | --- | ||
| 60 | 0.08 | γ-Terpinene | 10.76 | C10H16 | 137.132 | 67.0, 77.0, 110.0, 122.0 | --- | ||
| 61 | 0.03 | Esculin | 14.75 | C15H16O9 | 339.196 | 189.0, 255.2, 270.9, 324.1 | --- | ||
| 62 | 0.12 | Unknown | 16.87 | C18H14O3 | 279.102 | 149.0, 190.0, 205.1, 233.0, 261.0 | |||
| 63 | 1.44 | Unknown | 20.86 | C19H18O3 | 295.133 | 178.0, 191.0, 192.0, 206.1, 207.0, 207.1, 219.0, 221.1, 235.0 249.1, 252.0, 262.1, 265.0, 266.0, 277.1, 280.0 | |||
*: identified by library.
Figure 1The chemical structures of compounds tentatively identified in rhoifolin rich fraction (RRF) based on TLC-ESI/MS results, i.e., neohesperidin dihydrochalcone (1) (% peak area = 5.2), apigenin 7-O-neohesperidoside (rhoifolin) (2) (% peak area = 94.5), and isookanin-7-glucoside (flavanomarein) (3) (% peak area = 0.3).
Figure 2Impact of RRF on mono-species biofilms of (a) P. aeruginosa and (b) S. aureus isolates. The artistic symbol (*) represents a significant decrease in biofilm formation (p < 0.05).
Figure 3Impact of RRF on dual-species biofilms of (a) P1 + S1, (b) P2 + S2, (c) P3 + S3, and (d) P4 + S4. The artistic symbol (*) represents a significant decrease in biofilm formation (p < 0.05).
Figure 4Cytotoxicity of RRF on PBMCs by MTT assay. The IC50 was determined by three independent tests.
Figure 5Chart presenting the impact of RRF on the relative gene expression of COX-2, iNOS, IL-6, TNF-α, and NF-κB in LPS-induced PBMCs. The artistic symbol (*) represents a significant decrease in gene expression (p < 0.05).
Figure 6(a) Macroscopic visualization of the wound surface in treatment groups, Untreated control, Blank gel, Betadine, and RRF gel groups at day 0, day 5, and day 10. (b) Wound area in each test group (Untreated control, Blank gel, Betadine, RRF gel groups). Results were expressed as mean ± standard deviation (SD). Significant difference vs. the respective untreated control, each at p < 0.05.
Effects of RFF treatment on VEGF gene expression level, IL-6 level, IL-1β level, and NO content in skin wound model in rats.
| VEGF Gene | IL-6 Level | IL-1 | Skin NO Content (nmol/g Tissue) | |
|---|---|---|---|---|
| Untreated control | 0.4 ± 0.06 | 350.6 ± 8.65 | 442.3 ± 12.3 | 45.48 ± 3.65 |
| Control vehicle | 0.5 ± 0.09 | 356.3 ± 9.63 | 440 ± 10.9 | 48.53 ± 4.5 |
| Betadine | 1.1 ± 0.13 a | 145.3 ± 5.6 a | 136.8 ± 7.8 a | 20.12 ± 2.85 a |
| Rhoifolin rich | 1 ± 0.07 a | 70.1 ± 6.7a | 101.2 ± 8.12 a | 18.4 ± 2.12 a |
Results were expressed as mean ± SD (n = 8/group). Significant difference vs. a respective control, each at p ˂ 0.05.
Figure 7Effect of RRF treatment on (a) PDGF gene expression level, (b) KGF gene expression level, (c) Fibronectin gene expression level, and (d) MMP-1 gene expression level. Results were expressed as mean ± SD (n = 8/group). Significant difference vs. a respective untreated control, each at p < 0.05.
Figure 8Effect of RRF treatment on TGF-β immunostaining in different studied groups. (a) Section of the skin wound of the untreated control group that showed an ulcer with underlying granulation tissue that showed weak TGF-β staining [×100]. (b) Section of the skin wound of the blank gel group that showed granulation tissue with weak TGF-β staining [×100]. (c) Section of the treated skin with the Betadine group that showed partially healed skin and regenerated thin epidermis with moderate TGF-β staining [×100]. (d) Section of treated skin with the RRF group that showed complete wound healing with strong TGF-β staining [×100].
Figure 9Effect of RRF treatment on histopathological examination of skin tissues of different studied groups. (A1) Section of the skin wound of the untreated control group showed an ulcer covered by a scab (blue arrow) filled with acute and chronic inflammatory cellular infiltrate, granulation tissue, and fibrosis (red arrow) (H&E × 100). (A2) Section of the skin wound of the untreated control group showed granulation tissue consisting of newly formed blood vessels surrounded by acute and chronic inflammatory cellular infiltrate mainly giant cells (blue arrow) and collagenosis and fibrosis (green arrow) (H&E × 200). (B) Section of the skin wound of the blank gel group showed an ulcer covered by a scab (blue arrow) filled with acute and chronic inflammatory cellular infiltrate (red arrow), granulation tissue, and fibrosis (black arrow) (H&E × 100). (C) Section of the treated skin with the Betadine group showed partially healed skin, the regenerated epidermis (red arrows) with underlying granulation tissue (blue arrow) surrounded by fibrosis and collagenosis (green arrow) (H&E × 100). (D) Section of the treated skin with the RRF gel group showed complete wound healing with continuous epidermis (blue arrows) with underlying fibrosis and collagenosis (red arrow) (H&E × 100).